+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy



Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy



Journal of Hepatology 36(Suppl. 1): 245




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 035159471

Download citation: RISBibTeXText

DOI: 10.1016/s0168-8278(02)80880-7


Related references

Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B. Journal of Hepatology 38(Suppl. 2): 169, 2003

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastro-Enterologica Belgica 70(1): 20-24, 2007

Comparison of lamivudine monotherapy with lamivudine plus interferon alpha combination in patients with HBeAg positive chronic hepatitis B. Journal of Hepatology 34(Suppl. 1): 177-178, 2001

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. American Journal of Gastroenterology 100(11): 2463-2471, 2005

Lamivudine monotherapy and interferon plus lamivudine combination therapy in anti-HBe positive patients with chronic hepatitis B who have failed previously interferon treatment. Journal of Hepatology 34(Suppl. 1): 167, 2001

Durability of HBeAG seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy. Journal of Hepatology 34(Suppl. 1): 155, 2001

Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B. Scandinavian Journal of Gastroenterology 44(8): 1021-1022, 2010

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology and Hepatology 22(10): 1582-1588, 2007

A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Alimentary Pharmacology & Therapeutics 19(3): 339-347, 2004

Higher efficacy of sequential therapy of lamivudine and interferon compared to lamivudine monotherapy in HBeAg positive, chronic hepatitis B patients. Gastroenterology 123(1 Suppl.): 69, 2002

Interferon alpha-2a in combination therapies for the treatment of chronic hepatitis C in prior non-responders to interferon monotherapy. Journal of Hepatology 38(Suppl. 2): 168, 2003

Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B. Indian Journal of Gastroenterology 25(3): 136-139, 2006

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. Scandinavian Journal of Gastroenterology 34(2): 194-198, 1999